Physician profile
Michael R Powell
NPI 1437562139
$693.55
in general payments reported to CMS, 2019-2025
15 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.38 · 2020: $35.96 · 2021: $25.15 · 2022: $146 · 2023: $105 · 2024: $141 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.25 | 2022-2025 | |
| Amgen INC. | $113.08 | 2022-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $96.07 | 2020-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $94.78 | 2022-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Lilly USA, LLC | $42.26 | 2022-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $36.61 | 2021-2022 | |
| Pfizer INC. | $36.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $31.99 | 2019 | |
| Astellas Pharma US INC | $21.71 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $17.39 | 2019 | |
| Dexcom, INC. | $16.78 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $13.80 | 2024 | Trintellix |
| Daiichi Sankyo INC. | $12.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.47 | 2022 | |
| Glaxosmithkline, LLC. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.